Phio Pharmaceuticals - נכסים נקיים למניה בודדת PHIO

Phio Pharmaceuticals is recognized as a pioneer in creating INTASYL self-delivering RNA therapies to combat oncology. The bvps trend demonstrates changes in equity, where 1.08 indicates the current level. The stable operation of molecular screening laboratories supports the pace of research. Fundamental patents on gene suppression methods without the use of third-party carriers ensure a high barrier to entry.

Phio Pharmaceuticals (PHIO) is optimizing costs through the outsourcing of RNA research, which directly impacts its equity structure. The BVPS trend reflects the residual value of net assets per share, defined as the difference between all assets and liabilities, allowing investors to assess the business's intrinsic resilience and the risk of capital loss upon company liquidation.